Related Experiment Video
Updated: Jan 10, 2026
07:46
Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
25.9K
Obesity phenotypes and atherogenic dyslipidemias
Hun Jee Choe1, Talal Almas2, Ian J Neeland2,3
1Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, South Korea.
European Journal of Clinical Investigation
|November 21, 2025
Summary
Obesity phenotypes, particularly visceral fat, drive atherogenic dyslipidemias and cardiovascular disease risk. Targeted treatments and precision medicine are crucial for managing these interrelated conditions within the cardiovascular-kidney-metabolic syndrome.
Area of Science:
- Cardiovascular Medicine
- Metabolic Syndrome
- Obesity Research
Background:
- Obesity and atherogenic dyslipidemias are key drivers of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular-kidney-metabolic (CKM) syndrome.
- Obesity heterogeneity, especially visceral and ectopic fat, dictates dyslipidemia phenotypes like hypertriglyceridemia and altered lipoprotein levels.
Purpose of the Study:
- To review evidence linking obesity phenotypes to dyslipidemias and cardiovascular outcomes.
- To evaluate interventions for obesity-related lipid abnormalities.
Main Methods:
- Review of epidemiological studies, imaging, genetic data, and clinical trials.
- Evaluation of lifestyle, pharmacological, and surgical strategies.
Main Results:
- Visceral and ectopic fat accumulation are stronger predictors of adverse lipid profiles, insulin resistance, and cardiovascular events than BMI alone.
- Lifestyle interventions improve lipid metabolism independently of weight loss; novel pharmacotherapies and bariatric surgery offer significant metabolic benefits.
- Atherogenic dyslipidemias contribute to residual ASCVD risk even with low-density lipoprotein cholesterol reduction.
Conclusions:
- Atherogenic dyslipidemias characterize high-risk obesity phenotypes and are major contributors to ASCVD within the CKM framework.
- Precision medicine, including obesity phenotyping and targeted therapies, is essential to reduce the burden of dyslipidemias and their cardiovascular consequences.
Related Concept Videos
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
01:29Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
228
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
228
01:24Overview of Lipid Metabolism
4.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.7K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
162
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
162
01:21Drug Dosing: Obese Patients
204
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
204